Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Antiretroviral drug supply challenges in the era of scaling up ART in Malawi.

Schouten EJ, Jahn A, Ben-Smith A, Makombe SD, Harries AD, Aboagye-Nyame F, Chimbwandira F.

J Int AIDS Soc. 2011 Jul 6;14 Suppl 1:S4. doi: 10.1186/1758-2652-14-S1-S4. Review.

2.

Ensuring uninterrupted supplies of antiretroviral drugs in resource-poor settings: an example from Malawi.

Harries AD, Schouten EJ, Makombe SD, Libamba E, Neufville HN, Some E, Kadewere G, Lungu D.

Bull World Health Organ. 2007 Feb;85(2):152-5.

3.

Scaling up access to antiretroviral drugs in a middle-income country: public sector drug delivery in the Free State, South Africa.

Steyn F, Schneider H, Engelbrecht MC, van Rensburg-Bonthuyzen EJ, Jacobs N, van Rensburg DH.

AIDS Care. 2009 Jan;21(1):1-6. doi: 10.1080/09540120903131138.

4.

Trends and economic stress: a challenge to universal access to antiretroviral treatment in India.

Dhamija P, Bansal D, Medhi B.

Curr HIV Res. 2009 Jul;7(4):410-7.

PMID:
19601776
5.

A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries.

Waning B, Diedrichsen E, Moon S.

J Int AIDS Soc. 2010 Sep 14;13:35. doi: 10.1186/1758-2652-13-35.

6.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
7.

Antiretroviral procurement and supply chain management.

Ripin DJ, Jamieson D, Meyers A, Warty U, Dain M, Khamsi C.

Antivir Ther. 2014;19 Suppl 3:79-89. doi: 10.3851/IMP2903. Epub 2014 Oct 13. Review.

PMID:
25310145
8.

Lack of pre-antiretroviral care and competition from traditional healers, crucial risk factors for very late initiation of antiretroviral therapy for HIV--a case-control study from eastern Uganda.

Muhamadi L, Tumwesigye NM, Kadobera D, Marrone G, Wabwire-Mangen F, Pariyo G, Peterson S, Ekström AM.

Pan Afr Med J. 2011;8:40. Epub 2011 Apr 7.

9.

Simplifying ART cohort monitoring: can pharmacy stocks provide accurate estimates of patients retained on antiretroviral therapy in Malawi?

Tweya H, Feldacker C, Ben-Smith A, Harries AD, Komatsu R, Jahn A, Phiri S, Tassie JM.

BMC Health Serv Res. 2012 Jul 20;12:210. doi: 10.1186/1472-6963-12-210.

10.

Why did the scale-up of HIV treatment work? A case example from Malawi.

Harries AD, Makombe SD, Libamba E, Schouten EJ.

J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 2:S64-7. doi: 10.1097/QAI.0b013e31821f6bab.

PMID:
21857298
11.

Factors influencing global antiretroviral procurement prices.

Wirtz VJ, Forsythe S, Valencia-Mendoza A, Bautista-Arredondo S.

BMC Public Health. 2009 Nov 18;9 Suppl 1:S6. doi: 10.1186/1471-2458-9-S1-S6.

12.

The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.

Waning B, Diedrichsen E, Jambert E, Bärnighausen T, Li Y, Pouw M, Moon S.

BMC Pediatr. 2010 Oct 17;10:74. doi: 10.1186/1471-2431-10-74.

13.

The challenge to avoid anti-malarial medicine stock-outs in an era of funding partners: the case of Tanzania.

Mikkelsen-Lopez I, Shango W, Barrington J, Ziegler R, Smith T, deSavigny D.

Malar J. 2014 May 11;13:181. doi: 10.1186/1475-2875-13-181.

14.

Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets.

Waning B, Kyle M, Diedrichsen E, Soucy L, Hochstadt J, Bärnighausen T, Moon S.

Global Health. 2010 May 25;6:9. doi: 10.1186/1744-8603-6-9.

15.

Three years of HIV/AIDS care and treatment services in Tanzania: achievements and challenges.

Somi G, Matee M, Makene CL, Van Den Hombergh J, Kilama B, Yahya-Malima KI, Masako P, Sando D, Ndayongeje J, Rabiel B, Swai RO.

Tanzan J Health Res. 2009 Jul;11(3):136-43.

PMID:
20734710
16.

Early warning indicators for HIV drug resistance in Cameroon during the year 2010.

Billong SC, Fokam J, Nkwescheu AS, Kembou E, Milenge P, Tsomo Z, Dion GN, Aghokeng AF, Mpoudi EN, Ndumbe PM, Colizzi V, Elat Nfetam JB.

PLoS One. 2012;7(5):e36777. doi: 10.1371/journal.pone.0036777. Epub 2012 May 17.

17.

Scaling up antiretroviral therapy in Malawi-implications for managing other chronic diseases in resource-limited countries.

Harries AD, Zachariah R, Jahn A, Schouten EJ, Kamoto K.

J Acquir Immune Defic Syndr. 2009 Nov;52 Suppl 1:S14-6. doi: 10.1097/QAI.0b013e3181bbc99e. Review.

PMID:
19858929
18.

Reforming antiretroviral price negotiations and public procurement: the Mexican experience.

Adesina A, Wirtz VJ, Dratler S.

Health Policy Plan. 2013 Jan;28(1):1-10. doi: 10.1093/heapol/czs015. Epub 2012 Feb 28.

19.

Malawi's contribution to "3 by 5": achievements and challenges.

Libamba E, Makombe SD, Harries AD, Schouten EJ, Yu JK, Pasulani O, Mhango E, Aberle-Grasse J, Hochgesang M, Limbambala E, Lungu D.

Bull World Health Organ. 2007 Feb;85(2):156-60.

20.

HIV/AIDS related commodities supply chain management in public health facilities of Addis Ababa, Ethiopia: a cross-sectional survey.

Berhanemeskel E, Beedemariam G, Fenta TG.

J Pharm Policy Pract. 2016 Mar 31;9:11. doi: 10.1186/s40545-016-0060-z. eCollection 2016.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk